Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label acalabrutinib study in relapsed or refractory mantle cell lymphoma
NL-OMON53032Phase 2Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib in mantle cell lymphoma (MCL), sponsored by Acerta Pharma. Primary endpoints: Overall response rate, Duration of response and 2 more. Started Apr 2015; status: active, not recruiting.
02
Drugs
acalabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NL-OMON53032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53032.